Tag Archives: country

  • Future of BioPharma

    The Biopharma industry is an industry dependent on investment, therefore it is extremely vulnerable to the economic climate.  When the economy is booming so is the Biopharma industry, including pharmaceutical consulting firms, life sciences consulting firms, and pharmaceutical sales consulting firms all over the country.  But when the economy is in a downward trend, the biotech industry, not to mention service suppliers and vendors, are all affected. In today’s bad economy we all know this …

  • India, Strong Pharma Destination

    … local pharmaceutical market will experience a huge transformation in the years to come, reaching the top 10 around the year 2015.  This will definitely have an impact on the global pharma industry in regards to R&D. Previous estimations have valued India’s research market between $600 million to $1 billion dollars, and global clinical trials performed in this country are expected to continue growing importantly in the next few years. There are various reasons as to why India is such a …

  • Cost and Benefit in the Pharmaceutical Industry

    … percent of the money spent on marketing is not accounted for in the companies’ figures and books. This means that even more is spent on that part of the commercial process associated with marketing  pharmaceutical products. In all, it is estimated that a total of  $57.5 billion was spent on marketing needs on 2004, while only $31.5 billion was spent on Research and Development. A pharmaceutical company is crucial to the economic, social, and vital growth of a country. As a leading country in …

  • Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium

    ‘Funding Biopharma: Strategies for Reaching Investors in a Financial Crisis’ Draws Regional Biopharmaceutical Executives, Investment Leaders BASKING RIDGE, N.J., June 18 /PRNewswire/ — Biotech companies throughout the country are reeling from the economic recession with half of the industry’s 370 small-cap funds slated to run out of cash before 2010, regional biopharmaceutical executives and investment market leaders concluded during a life sciences symposium presented by …

  • 5 Things To Avoid When Launching A Health Care Product

    … PRODUCT FOR ALL COUNTRIES: Popular, soft, and creamy cosmetics in the North can create big allergies in the South. Clinical tests will help you determine what things to consider among regional or racial differences. Purchasing habits, treatments, and type of consumption vary from one country to another. If you stick to only one type of product, with no variation, you may lose your share in a country’s market. 5.    NO INFORMATION: Your product looks nice, has a catchy name, a beautiful box …

  • Outsourcing Biopharmaceutical Manufacturing

    The Market Given their specificity, biopharmaceuticals can cure diseases, not just treat symptoms, whilst often causing fewer side effects.  As the number of new diseases that can be treated with biopharmaceuticals increases, so does the demand for these around the world.  Biologics, which constitute 30% of all therapeutic compounds being developed, are very popular among Pharma companies and the country’s protein therapeutics market is expected to grow significantly by 2010.  Within …

  • Universal Health Coverage Dilemma

    … from treatment of people who can’t afford treatment is both affecting the health industry and presenting a moral dilemma to the country. Well, some stats are in, and they suggest that ERs aren’t really filled with the uninsured. From 2005 to 2007, the number of trips to the ER rose 7%. This data for two years may be too little to draw any conclusions. However, according to a study last year by the Annals of Emergency Medicine, between 1996 and 2004 nationwide visits to the ER increased by …